Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double-blind, multicenter clinical trial

Combination of Clopidogrel and Aspirin after Transient Ischemic Attack (POINT Trial)

Study objective: This study is designed to learn whether the combination of aspirin and clopidogrel reduces the risk of stroke, heart attacks, and other complications related to reduced supply of oxygen and nutrients to tissues (ischemia), compared to aspirin alone.

Am I eligible? Participants should be 18 years or older who have just had a transient ischemic attack (TIA) or a minor stroke. Eligibility will be determined at a screening visit.

What is involved? Those who qualify will be assigned to 1 of 2 treatment groups. One group will put on a daily regimen of clopidogrel tablets and aspirin for 90 days. The other group will receive a daily regimen of placebo (an inactive substance) and aspirin for 90 days.

keywords: Clopidogrel, aspirin, transient ischemic attack, POINT, stroke, heart attack

 

Principal Investigator

Michael Abraham, MD

Study Contact

Michael Abraham, mabraham@kumc.edu, 913-588-6970

ClinicalTrials.gov #

NCT00991029